Navigation Links
Going a step Further: Phase IV and Post-Marketing Observational Studies add Value to new Therapies, life Science Webinar Hosted by Xtalks
Date:4/23/2013

Toronto, Canada (PRWEB) April 23, 2013

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs.

Post-Approvals Clinical & Epidemiology Studies (PACES), including Post-Marketing Observational Studies (PMOS) and Phase IV studies, are the only sources of information that allows the assessment of real–life effectiveness and safety. These studies are ideal for generating data regarding patient adherence/compliance to treatment and its impact on effectiveness. Practice patterns and adherence to treatment guidelines by physicians can only be assessed with PACES.

In an exciting new webinar, Dr. John Samplis, Chief Scientific Officer at JSS Medical Research Inc., will cover:

  •     The objectives of PMOS and Phase IV studies
  •     Strategies for designing meaningful PMOS and Phase IV studies
  •     Important considerations when conducting PMOS and Phase IV studies, including: Objectives, Study Design, Statistics, Randomization, Non-standardized follow-up, Data Analysis
  •     The advantages and disadvantages of PMOS and Phase IV compared to other post-approval studies design
  •     Examples of PMOS and Phase IV.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtks.in/xto591p

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10652903.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
2. Jennifer Aniston's People's Choice Awards Dress Worries Animal Welfare Advocates; Going Green News Site My Cleaning Products Comments It Was a Bad Pick
3. Arnold Schwarzenegger's Climate Change Law Gets Enacted; Going Green News Site Green Bean Cleaning Urges Public to Help It Help Build a Greener Earth
4. Sitting still or going hunting: Which works better?
5. New fuel cell keeps going after the hydrogen runs out
6. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
7. Blocked holes can enhance rather than stop light going through
8. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
9. Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
10. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... New York , December 9, 2016 ... states that the top five players in the  Global ... 62.7% in the overall market in 2015. Players such ... Perkin Elmer have remained dominant in the global market ... efforts to ensure product innovation. Product upgrades and timely ...
(Date:12/8/2016)... 8, 2016  The Board of Directors of the ... Western Pennsylvania,s only pure life sciences investment ... with the succession plan developed by the Nominating and ... James (Jim) F. Jordan is selected to ... John W. Manzetti , who is elected to the ...
(Date:12/8/2016)... , December 8, 2016 AskLinkerReports.com ... comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research Report. ... application, and industry chain overview are all covered in the ... analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):